Deep Learning-Based Modeling of Transcriptional Reprogramming in Cancer Cell State Transitions

Abstract

Cancer cell state transitions, including epithelial‑mesenchymal plasticity, drug‑tolerant persistence, and metastatic reprogramming, are governed by complex transcriptional networks whose dynamics remain poorly understood. Deep learning models have emerged as powerful tools to infer regulatory logic from high‑throughput genomic, epigenomic, and transcriptomic data. This paper examines the system‑level challenges and architectural trade‑offs in deploying deep learning for modeling transcriptional reprogramming. We analyze the structural requirements of transformer‑based and graph neural network architectures that capture long‑range chromatin interactions and phase‑separation phenomena, with specific attention to the role of condensate‑mediated transcriptional control. Data infrastructure issues, including the integration of multi‑omic datasets from heterogeneous clinical cohorts, are discussed in relation to model robustness and generalizability. We further explore fairness and governance concerns arising from algorithmic bias across ancestry groups and the ethical implications of using deep learning for therapeutic stratification. Sustainability and deployment considerations, such as computational cost, interpretability, and regulatory approval pathways, are critically assessed. Cross‑domain comparisons with deep learning applications in structural biology and natural language processing illuminate unique constraints in the oncological context. The paper concludes by outlining a policy‑oriented framework for responsible, equitable, and reproducible AI‑driven research in cancer transcriptomics, emphasizing the need for federated learning infrastructures and transparent model validation.